Understanding the mechanism responsible for the impaired keratinocytes migration in diabetes by characterizing the excessive MMP9 expression mediated by FOXO1 will help set the basis for clinical application of a FOXO1 antagonist in treating diabetic wounds. This evidence concerns the gene FOXO1 and diabetes mellitus.